Literature DB >> 6143816

Relative efficacy of prenalterol and pirbuterol for beta-1 adrenoceptors: measurement of agonist affinity by alteration of receptor number.

T P Kenakin, D Beek.   

Abstract

Both prenalterol and pirbuterol are partial agonists (when compared to isoproterenol) in rat left atria. Schild analysis with the beta-1 adrenoceptor selective antagonist atenolol indicated that all three agonists stimulate beta-1 adrenoceptors in this preparation. Atria from rats implanted with mini-osmotic pumps which delivered isoproterenol (400 micrograms kg-1 hr-1) s.c. for 4 days were 9 times less sensitive than control, to isoproterenol, and produced no responses to either prenalterol or pirbuterol. Schild analysis with atenolol on these desensitized atria indicated a homogeneous population of beta-1 adrenoceptors. In the desensitized atria, both prenalterol and pirbuterol functioned as competitive antagonists of responses to isoproterenol and Schild analysis yielded estimates of the equilibrium dissociation constants (Kp) of prenalterol (0.09 micron) and pirbuterol (2 micron) in these tissues. The estimates of Kp were utilized to calculate the relative efficacy of pirbuterol and prenalterol; pirbuterol was shown to have 2.3 times the efficacy of prenalterol on beta-1 adrenoceptors. The implications of this method as a means of calculating the Kp for partial agonists are discussed. These data also serve as a caveat to the use of pirbuterol in the determination of functional cardiac beta adrenoceptor subtypes in experimental animals and in man.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6143816

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Desensitization and functional antagonism by beta-adrenoceptor and muscarinic receptor agonists, respectively: a comparison with receptor alkylation for calculation of apparent agonist affinity.

Authors:  R M Eglen; W W Montgomery; R L Whiting
Journal:  Br J Pharmacol       Date:  1991-08       Impact factor: 8.739

2.  A new ligand for the urotensin II receptor.

Authors:  Valeria Camarda; Remo Guerrini; Evi Kostenis; Anna Rizzi; Girolamo Calò; Almut Hattenberger; Marina Zucchini; Severo Salvadori; Domenico Regoli
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

3.  Pharmacological characterization of CGP 12177 at the human beta(2)-adrenoceptor.

Authors:  Jillian G Baker; Ian P Hall; Stephen J Hill
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

4.  Beta 1- and beta 2-adrenoceptor binding and functional response in right and left atria of rat heart.

Authors:  E N Juberg; K P Minneman; P W Abel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-09       Impact factor: 3.000

Review 5.  Pirbuterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible bronchospastic disease.

Authors:  D M Richards; R N Brogden
Journal:  Drugs       Date:  1985-07       Impact factor: 9.546

6.  Inhibition of some aspects of acute inflammation of guinea-pig lung by intraperitoneal dexamethasone and mifepristone: demonstration of agonist activity of mifepristone in the guinea-pig.

Authors:  C J Whelan; S C Hughes; G P Wren
Journal:  Inflamm Res       Date:  1995-03       Impact factor: 4.575

7.  Pharmacology and direct visualisation of BODIPY-TMR-CGP: a long-acting fluorescent beta2-adrenoceptor agonist.

Authors:  Jillian G Baker; Ian P Hall; Stephen J Hill
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

8.  Beta-adrenoceptor antagonists (non-selective as well as beta 1-selective) with partial agonistic activity decrease beta 2-adrenoceptor density in human lymphocytes. Evidence for a beta 2-agonistic component of the partial agonistic activity.

Authors:  O E Brodde; R Schemuth; M Brinkmann; X L Wang; A Daul; U Borchard
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-06       Impact factor: 3.000

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.